HomeInsightsPE

Glenmark Life Sciences Ltd PE Ratio

Glenmark Life Sciences Ltd PE Ratio

stocks purchased

₹ 1.4 Cr

Volume Transacted

(Nov 25, 2024)

stocks purchased

13.1 K

Stocks Traded

(Nov 25, 2024)

Last Updated on: Nov 25, 2024

Image

Glenmark Life Sciences Ltd

NSE: GLS

PE

30.4

Last updated on: Nov 25, 2024

Key Highlights

  • The P/E Ratio of Glenmark Life Sciences Ltd is 30.4 as of 25 Nov 15:30 PM .
  • The P/E Ratio of Glenmark Life Sciences Ltd changed from 13.4 on March 2022 to 20.2 on March 2024 . This represents a CAGR of 14.66% over 3 years.
  • The Latest Trading Price of Glenmark Life Sciences Ltd is ₹ 1093 as of 25 Nov 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.7. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Glenmark Life Sciences Ltd

No data available

Company Fundamentals for Glenmark Life Sciences Ltd

No data available

Image

Glenmark Life Sciences Ltd

NSE: GLS

Share Price

₹ 1093.25

44.35 (4.23%)

stock direction

Last updated on: Nov 25, 2024

Market Price of Glenmark Life Sciences Ltd

1M

1Y

3Y

5Y

Monitoring Glenmark Life Sciences Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 20241048.9
21 Nov 20241081.15
19 Nov 20241084
18 Nov 20241082.05
14 Nov 20241080.35
13 Nov 20241060.65
12 Nov 20241096.1
11 Nov 20241091.1
08 Nov 20241094.65
07 Nov 20241117.1

SWOT Analysis Of Glenmark Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Glenmark Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Glenmark Life Sciences Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Glenmark Life Sciences Ltd3012,852
Sun Pharmaceuticals Industries Ltd384,31,352
Divis Laboratories Ltd861,59,265
Cipla Ltd261,20,033
Torrent Pharmaceuticals Ltd611,07,301
Mankind Pharma Ltd481,02,231

Key Valuation Metric of Glenmark Life Sciences Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Glenmark Life Sciences Ltd

No data available

* All values are in crore

Historical Revenue of Glenmark Life Sciences Ltd

No data available

* All values are in crore

Historical EBITDA of Glenmark Life Sciences Ltd

No data available

* All values are in crore

Historical Net Profit of Glenmark Life Sciences Ltd

No data available

* All values are in crore

Historical Dividend Payout of Glenmark Life Sciences Ltd

No data available

* All values are in %

About Glenmark Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

Glenmark Life Sciences Ltd News Hub

News

Glenmark Life Sciences Ltd leads gainers in 'A' group

Tamilnad Mercantile Bank Ltd, Marico Ltd, Rossari Biotech Ltd and Nestle India Ltd are amo...

Read more

2024-08-05 00:00:00

News

Glenmark Life Sciences AGM scheduled

Glenmark Life Sciences announced that the Annual General Meeting (AGM) of the company will...

Read more

2024-09-06 00:00:00

News

Glenmark Life drops after PAT slides 20% YoY to Rs 95 crore in Q2

Profit before tax (PBT) dropped 19.8% YoY to Rs 127.46 crore in the quarter ended 30 Septe...

Read more

2024-10-25 00:00:00

News

Glenmark Life Sciences standalone net profit declines 19.72% in the September 2024 quarter

Net profit of Glenmark Life Sciences declined 19.72% to Rs 95.32 crore in the quarter ende...

Read more

2024-10-25 00:00:00

News

Glenmark Life Sciences announces board meeting date

Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 24 ...

Read more

2024-10-17 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Glenmark Life Sciences Ltd

What is the current PE Ratio of Glenmark Life Sciences Ltd?

The Current PE Ratio of Glenmark Life Sciences Ltd is 30.35 as on 25 Nov 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 25 Nov 2024.

What was the PE Ratio of Glenmark Life Sciences Ltd last year?

The PE Ratio of Glenmark Life Sciences Ltd was 10.28 last year, now the PE ratio is 30.35, showing a year-on-year growth of 195.2%.

What does the PE Ratio of Glenmark Life Sciences Ltd indicate about its stock?

The PE Ratio of Glenmark Life Sciences Ltd is 30.35. This ratio indicates that investors are willing to pay 30.35 times the earnings per share for each share of Glenmark Life Sciences Ltd.

What is the PE Ratio Growth of Glenmark Life Sciences Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Glenmark Life Sciences Ltd grew by 195.2% whereas, the EPS ratio grew by -14.5.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*